Ngā hua rapu - David Irwin
- E whakaatu ana i te 1 - 20 hua o te 33
- Haere ki te Whārangi Whai Ake
-
1
The Splenic Syndrome in Individuals with Sickle Cell Trait mā Jessica Goodman, Kathryn Hassell, David Irwin, Ewa H. Witkowski, Rachelle Nuss
I whakaputaina 2014Artigo -
2
RhoGTPase in Vascular Disease mā Derek Strassheim, Evgenia Gerasimovskaya, David Irwin, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor
I whakaputaina 2019Revisão -
3
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer mā Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus, David Irwin, James L. Speyer, Alan J. Koletsky, Paula Klein, Tariq Sabir, Lori Kronish
I whakaputaina 2002Artigo -
4
-
5
Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease mā Ayla Yalamanoglu, Jeremy W. Deuel, Ryan Hunt, Jin Hyen Baek, Kathryn L. Hassell, Katie Redinius, David Irwin, Dominik J. Schaer, Paul W. Buehler
I whakaputaina 2018Artigo -
6
-
7
Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dos... mā David Irwin, Jin Hyen Baek, Kathryn L. Hassell, Rachelle Nuss, Paul Eigenberger, Christina Lisk, Zoe Loomis, Joanne Maltzahn, Kurt R. Stenmark, Eva Nozik‐Grayck, Paul W. Buehler
I whakaputaina 2015Artigo -
8
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma mā Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Eli Gabayan, Amitabha Mazumder, David P. Schenkein, John Crowley
I whakaputaina 2005Artigo -
9
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma mā Paul G. Richardson, Bart Barlogie, James R. Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David P. Schenkein, Kenneth C. Anderson
I whakaputaina 2005Artigo -
10
Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study mā Stephanie J. Lee, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Jesús F. San Miguel, Bruce Crawford, Joseph M. Massaro, Ravinder Dhawan, Sanjay Gupta, Kenneth C. Anderson
I whakaputaina 2008Artigo -
11
Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism mā Paul W. Buehler, Jin Hyen Baek, Christina Lisk, Ian Connor, Timothy J. Sullivan, Douglas J. Kominsky, Susan M. Majka, Kurt R. Stenmark, Eva Nozik‐Grayck, J. Bonaventura, David Irwin
I whakaputaina 2012Artigo -
12
Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma mā Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio
I whakaputaina 2009Artigo -
13
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension mā Douglas D. Lemon, Todd R. Horn, Maria A. Cavasin, Mark Y. Jeong, Kurt Haubold, Carlin S. Long, David Irwin, Sylvia A. McCune, Eunhee Chung, Leslie A. Leinwand, Timothy A. McKinsey
I whakaputaina 2011Artigo -
14
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial mā Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, M. Biakhov, David Irwin, Norbert Marschner, C. Slabber, George Fountzilas, A. Garin, N.G.F. Abecasis, W. Baronius, G. Steger, T Südhoff, C. Giorgetti, Peter Reichardt
I whakaputaina 2005Artigo -
15
Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma mā Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Jesús F. San Miguel, Jamie Cavenagh, Kenneth C. Anderson
I whakaputaina 2007Artigo -
16
Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension mā Eva Nozik‐Grayck, Crystal Woods, Joann M. Taylor, Richard K.P. Benninger, R. Daniel Johnson, Leah R. Villegas, Kurt R. Stenmark, David G. Harrison, Susan M. Majka, David Irwin, Kathryn N. Farrow
I whakaputaina 2014Artigo -
17
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma mā Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Rubén Niesvizky, Raymond Alexanian, Steven Limentani, Melissa Alsina, Julian Adams, Michael Kauffman, Dixie‐Lee Esseltine, David P. Schenkein, Kenneth C. Anderson
I whakaputaina 2004Artigo -
18
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multip... mā Rubén Niesvizky, Paul G. Richardson, S. Vincent Rajkumar, Morton Coleman, Laura Rosiñol, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Anthony Boral, Dixie‐Lee Esseltine, Kenneth C. Anderson, Joan Bladé
I whakaputaina 2008Artigo -
19
A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak mā David Irwin, Joe M. McCord, Eva Nozik‐Grayck, Ginny Beckly, Ben Foreman, Timothy J. Sullivan, Molly White, Joseph T. Crossno, Damian M. Bailey, Sonia C. Flores, Susan M. Majka, Dwight J. Klemm, Martha C. Tissot van Patot
I whakaputaina 2009Artigo -
20
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma mā Paul G. Richardson, Sundar Jagannath, Mohamad A. Hussein, James R. Berenson, Seema Singhal, David Irwin, Stephanie Williams, William Bensinger, Ashraf Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Kenneth C. Anderson
I whakaputaina 2009Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Multiple myeloma
Bortezomib
Dexamethasone
Oncology
Chemistry
Biology
Surgery
Hypoxia (environmental)
Organic chemistry
Oxygen
Chemotherapy
Biochemistry
Endocrinology
Gastroenterology
Pulmonary hypertension
Adverse effect
Immunology
Neutropenia
Pharmacology
Proteasome inhibitor
Pathology
Astrobiology
Cardiology
Clinical trial
Haptoglobin
Hemoglobin
Physics
Pulmonary artery